Drug General Information
Drug ID
D0EO2C
Former ID
DIB012871
Drug Name
LY-2881835
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [523492]
Company
Eli Lilly & Co
Structure
Download
2D MOL

3D MOL

Target and Pathway
Target(s) GPR40 Target Info Modulator [544438]
KEGG Pathway Insulin secretion
Reactome G alpha (q) signalling events
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
WikiPathways GPCRs, Class A Rhodopsin-like
Incretin Synthesis, Secretion, and Inactivation
Gastrin-CREB signalling pathway via PKC and MAPK
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 523492ClinicalTrials.gov (NCT01358981) A Study of LY2881835 in Healthy People and People With Diabetes. U.S. National Institutes of Health.
Ref 544438Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.